CoChat

The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.

Challenges and opportunities in NASH drug development

Abstract

Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical need, as no licensed drugs have been approved thus far. Currently, histopathological assessment of liver biopsies is mandatory as a primary endpoint for conditional drug approval. This requirement represents one of the main challenges in the field, as there is substantial variability in this invasive histopathological assessment, which leads to dramatically high screen-failure rates in clinical trials. Over the past decades, several non-invasive tests have been developed to correlate with liver histology and, eventually, outcomes to assess disease severity and longitudinal changes non-invasively. However, further data are needed to ensure their endorsement by regulatory authorities as alternatives to histological endpoints in phase 3 trials. This Review describes the challenges of drug development in NAFLD-NASH trials and potential mitigating strategies to move the field forward.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02242-6

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 125 references

Research works printed but not linked: 6

  1. Noureddin, M. & Rinella, M. E. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin. Liver Dis. 19, 361–379 (2015).
  2. Björnsson, E. S. Incidence and outcomes of DILI in Western patients. Clin. Liver Dis. 4, 9–11 (2014).
  3. Guo, T. A tool to help you decide (detect potentially serious liver injury). In Annual Conference of the American Association for the Study of Liver Diseases (AASLD, 2008).
  4. Guo, T. How a SAS/IntrNet tool was created at the FDA for the detection of potential drug-induced liver injury using data with CDISC standard. In Western Users of SAS Software Annual Conference (WUSS, 2009).
  5. Pokkalla, H. et al. Machine learning models accurately interpret liver histology in patients with nonalcoholic steatohepatitis (NASH). Hepatology 70, 121A–122A (2019).
  6. Alkhouri, N. & McCullough, A. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol. Hepatol. 8, 661–668 (2012).

Cited by

See all 393

Metadata

Authors
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N.
Affiliations
  • University of Oxford (GB)
  • Mayo Clinic (US)
  • Houston Methodist (US)
  • Arizona Liver Health (US)
Corresponding author
Harrison, Stephen A.
Venue
Nature Medicine
Published
2023-03
Volume
29
Issue
3
Pages
562-573
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4323670059
Cited by
353
References
125
Citations by year
2026: 70 · 2025: 112 · 2024: 130 · 2023: 41
FWCI
13.99
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, histopathological assessment, liver biopsy, non-invasive tests, biomarkers, clinical trial endpoints, screen failure, trial design, disease severity assessment
MeSH terms
Drug Development, Humans, Liver, Liver Cirrhosis, Severity of Illness Index, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Challenges and opportunities in NASH drug development. https://app.cochat.ai/papers/10.1038/s41591-023-02242-6
The paper
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023). Challenges and opportunities in NASH drug development. Nature Medicine. https://doi.org/10.1038/s41591-023-02242-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.